CoChat

Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode

Open access
Georgakopoulos, Nikolaos, Talapatra, Sandeep, Dikovskaya, Dina, Dayalan Naidu, Sharadha, Higgins, Maureen, Gatliff, Jemma, Ayhan, Aysel, Nikoloudaki, Roxani, Schaap, Marjolein, Valko, Klara, Javid, Farideh, Dinkova-Kostova, Albena T., Kozielski, Frank, Wells, Geoffrey · 2022 · Journal of Medicinal Chemistry

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Inhibitors of Kelch-like ECH-associated protein 1 (Keap1) increase the activity of the transcription factor nuclear factor erythroid 2-related factor 2 (Nrf2) by stalling its ubiquitination and degradation. This enhances the expression of genes encoding proteins involved in drug detoxification, redox homeostasis, and mitochondrial function. Nrf2 activation offers a potential therapeutic approach for conditions including Alzheimer's and Parkinson's diseases, vascular inflammation, and chronic obstructive airway disease. Non-electrophilic Keap1-Nrf2 protein-protein interaction (PPI) inhibitors may have improved toxicity profiles and different pharmacological properties to cysteine-reactive electrophilic inhibitors. Here, we describe and characterize a series of phenyl bis-sulfonamide PPI inhibitors that bind to Keap1 at submicromolar concentrations. Structural studies reveal that the compounds bind to Keap1 in a distinct "peptidomimetic" conformation that resembles the Keap1-Nrf2 ETGE peptide complex. This is different to other small molecule Keap1-Nrf2 PPI inhibitors, including bicyclic aryl bis-sulfonamides, offering a starting point for new design approaches to Keap1 inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acs.jmedchem.2c00457

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 (A) Structure of the Keap1 Kelch domain (PDB entry 4IQK) shown as a surface representation, the sub-pockets of the Nrf2 binding site are shown: P1 (maroon residues 415, 461, 462, 478, 483, and 508), P2 (green residues, 363, 380, 381, and 414), P3 (blue residues, 364, 509, 556, 571, 602, and 603), P4 (yellow residues, 334, 572, and 577), and P5 (purple residues, 525, 530, and 555); (B) the structures of published Keap1-Nrf2 PPI inhibitors containing a naphthalene central ring system. FP values for compounds 1–8 are IC50s determined using FP; SA values are Kds from a secondary assay; (a) Kd determined using SPR assay; (b) Kd determined using ITC; (c) fluorescence anisotropy assay; and (d) not determined (DSF thermal shift = −5 °C).13,14,17,18,24,27
Figure 1 (A) Structure of the Keap1 Kelch domain (PDB entry 4IQK) shown as a surface representation, the sub-pockets of the Nrf2 binding site are shown: P1 (maroon residues 415, 461, 462, 478, 483, and 508), P2 (green residues, 363, 380, 381, and 414), P3 (blue residues, 364, 509, 556, 571, 602, and 603), P4 (yellow residues, 334, 572, and 577), and P5 (purple residues, 525, 530, and 555); (B) the structures of published Keap1-Nrf2 PPI inhibitors containing a naphthalene central ring system. FP values for compounds 1–8 are IC50s determined using FP; SA values are Kds from a secondary assay; (a) Kd determined using SPR assay; (b) Kd determined using ITC; (c) fluorescence anisotropy assay; and (d) not determined (DSF thermal shift = −5 °C).13,14,17,18,24,27CC BY · PubMed Central
Figure 2 (A) Structures of compounds 9–12; (B,C) co-crystallized structure of 1 bound to the Keap1 Kelch domain (PDB entry 4IQK); (D–G) docked conformations of compounds 1, 4, 11, and 12, respectively, bound to the corresponding 4IQK Keap1 Kelch domain.
Figure 2 (A) Structures of compounds 9–12; (B,C) co-crystallized structure of 1 bound to the Keap1 Kelch domain (PDB entry 4IQK); (D–G) docked conformations of compounds 1, 4, 11, and 12, respectively, bound to the corresponding 4IQK Keap1 Kelch domain.CC BY · PubMed Central
Scheme 1 Synthetic Route to Compounds 10–11 and 31–34 Reagents and conditions: (a) Fe, AcOH, EtOH/H2O, 65 °C, 2 h or SnCl2·2H2O, EtOH, 60 °C, 2 h; (b) 4-methoxybenzenesulfonyl chloride, pyridine, DMAP, DCM, rt, o/n; (c) ethyl bromoacetate, K2CO3, DMF, rt, 6 h; and (d) 1 N NaOH, THF//MeOH (1:1), rt, 2 h.
Scheme 1 Synthetic Route to Compounds 10–11 and 31–34 Reagents and conditions: (a) Fe, AcOH, EtOH/H2O, 65 °C, 2 h or SnCl2·2H2O, EtOH, 60 °C, 2 h; (b) 4-methoxybenzenesulfonyl chloride, pyridine, DMAP, DCM, rt, o/n; (c) ethyl bromoacetate, K2CO3, DMF, rt, 6 h; and (d) 1 N NaOH, THF//MeOH (1:1), rt, 2 h.CC BY · PubMed Central
Scheme 2 Synthetic Route to Compounds 35–39 Reagents and conditions: (a) triethylsilane, 5% Pd/C, EtOAc/EtOH (9:1 v/v), rt, 2 h, 61%; (b) R–X, K2CO3, acetone, rt, o/n; and (c) 1 N NaOH, THF//MeOH (1:1), rt, 2 h.
Scheme 2 Synthetic Route to Compounds 35–39 Reagents and conditions: (a) triethylsilane, 5% Pd/C, EtOAc/EtOH (9:1 v/v), rt, 2 h, 61%; (b) R–X, K2CO3, acetone, rt, o/n; and (c) 1 N NaOH, THF//MeOH (1:1), rt, 2 h.CC BY · PubMed Central
Scheme 3 Synthetic Route to Compounds 40–42, 51, and 52 Reagents and conditions: (a) Boc2O, (NH4)2CO3, pyridine, DMF, Ar, 0 °C to rt, 18 h, 74%; (b) bromoacetonitrile, K2CO3, DMF, rt, 8 h, 59%; (c) NaN3, NH4Cl, DMF, 100 °C, o/n; (d) 4-methoxybenzenesulfonyl chloride, DCM, pyridine, rt, o/n; (e) ethyl bromoacetate, K2CO3, DMF, rt, 8 h; (f) SnCl2·2H2O, EtOH, 65 °C, 1 h; and (g) 1 N NaOH, THF/MeOH (1:1 v/v), 2 h.
Scheme 3 Synthetic Route to Compounds 40–42, 51, and 52 Reagents and conditions: (a) Boc2O, (NH4)2CO3, pyridine, DMF, Ar, 0 °C to rt, 18 h, 74%; (b) bromoacetonitrile, K2CO3, DMF, rt, 8 h, 59%; (c) NaN3, NH4Cl, DMF, 100 °C, o/n; (d) 4-methoxybenzenesulfonyl chloride, DCM, pyridine, rt, o/n; (e) ethyl bromoacetate, K2CO3, DMF, rt, 8 h; (f) SnCl2·2H2O, EtOH, 65 °C, 1 h; and (g) 1 N NaOH, THF/MeOH (1:1 v/v), 2 h.CC BY · PubMed Central
Scheme 4 Synthetic Route to Compounds 12 and 58–61 Reagents and conditions: (a) 4-R1-PhSO2Cl, pyridine, DMAP, DMF, 100 °C, o/n; (b) amine, EDCI·HCl, DMAP, DMF, o/n; (c) bromoacetonitrile or bromoacetamide, K2CO3, DMF, rt, o/n; (d) ethyl bromoacetate, K2CO3, DMF, rt, o/n; and (e) 1 N NaOH, THF/MeOH (1:1 v/v), o/n.
Scheme 4 Synthetic Route to Compounds 12 and 58–61 Reagents and conditions: (a) 4-R1-PhSO2Cl, pyridine, DMAP, DMF, 100 °C, o/n; (b) amine, EDCI·HCl, DMAP, DMF, o/n; (c) bromoacetonitrile or bromoacetamide, K2CO3, DMF, rt, o/n; (d) ethyl bromoacetate, K2CO3, DMF, rt, o/n; and (e) 1 N NaOH, THF/MeOH (1:1 v/v), o/n.CC BY · PubMed Central
Figure 3 (A–C) Bound conformation of compound 11 (green in A and B, purple in C) co-crystallized with the Keap1 Kelch domain; (D) overlay of the bound conformation of 11 and the ETGE peptide bound to Keap1 (PDB entry 2FLU);29 (E) comparison of the Keap1 Kelch domain binding pocket in the compound 11 co-crystal structure (cyan) and the 2FLU ETGE peptide co-crystal (blue); (F) comparison of the Keap1 Kelch domain binding pocket in the compound 11 co-crystal structure (cyan) and the compound 1 co-crystal structure (green).19
Figure 3 (A–C) Bound conformation of compound 11 (green in A and B, purple in C) co-crystallized with the Keap1 Kelch domain; (D) overlay of the bound conformation of 11 and the ETGE peptide bound to Keap1 (PDB entry 2FLU);29 (E) comparison of the Keap1 Kelch domain binding pocket in the compound 11 co-crystal structure (cyan) and the 2FLU ETGE peptide co-crystal (blue); (F) comparison of the Keap1 Kelch domain binding pocket in the compound 11 co-crystal structure (cyan) and the compound 1 co-crystal structure (green).19CC BY · PubMed Central
Figure 4 Dose-dependent induction of NQO1 [NAD(P)H-dependent quinone oxidoreductase-1] by selected (A) Keap1-Nrf2 PPI inhibitors: 10 (◀), 11 (▼), 31 (▲), 32 (●), 36 (⧫), and 38 (■) and (B) electrophilic Nrf2 activators: DMF (★) and CDDO-Me (▶).
Figure 4 Dose-dependent induction of NQO1 [NAD(P)H-dependent quinone oxidoreductase-1] by selected (A) Keap1-Nrf2 PPI inhibitors: 10 (◀), 11 (▼), 31 (▲), 32 (●), 36 (⧫), and 38 (■) and (B) electrophilic Nrf2 activators: DMF (★) and CDDO-Me (▶).CC BY · PubMed Central
Figure 5 Induction of the Nrf2-transcriptional targets Nqo1 (A), Hmox1 (B), Gstp (C), Gclc (D), and Gclc (E) in Hepa1c1c7 cells (n = 3) by compound 11 (50 μM). The data are represented graphically as mean values ± 1 standard deviation (SD). Student’s t-test was used to test for statistical significance, and in all cases, the difference in gene expression between vehicle- and compound 11-treated cells was statistically significant (p < 0.05).
Figure 5 Induction of the Nrf2-transcriptional targets Nqo1 (A), Hmox1 (B), Gstp (C), Gclc (D), and Gclc (E) in Hepa1c1c7 cells (n = 3) by compound 11 (50 μM). The data are represented graphically as mean values ± 1 standard deviation (SD). Student’s t-test was used to test for statistical significance, and in all cases, the difference in gene expression between vehicle- and compound 11-treated cells was statistically significant (p < 0.05).CC BY · PubMed Central
Figure 6 SARs for compounds 10–12, 31–42, 51–52, and 58–61.
Figure 6 SARs for compounds 10–12, 31–42, 51–52, and 58–61.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Research works printed but not linked: 1

  1. Valko, K. L. Physicochemical and Biomimetic Properties in Drug Discovery: Chromatographic Techniques for Lead Optimization; John Wiley & Sons, Inc.: New Jersey, USA, 2014; p 450.

Cited by

See all 36

Metadata

Authors
Georgakopoulos, N., Talapatra, S., Dikovskaya, D., Dayalan Naidu, S., Higgins, M., Gatliff, J., Ayhan, A., Nikoloudaki, R., Schaap, M., Valko, K., Javid, F., Dinkova-Kostova, A. T., Kozielski, F., & Wells, G.
Affiliations
  • Stevenage Bioscience Catalyst (GB)
  • UCL School of Pharmacy (GB)
  • University of Dundee (GB)
  • Jacqui Wood Cancer Centre, Division of Cellular Medicine, School of Medicine, University of Dundee, Dundee DD1 9SY, Scotland, U.K.
  • University of Huddersfield (GB)
Corresponding author
Wells, Geoffrey
Venue
Journal of Medicinal Chemistry
Published
2022-05-12
Volume
65
Issue
10
Pages
7380-7398
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W4280585810
Cited by
33
References
48
Citations by year
2026: 7 · 2025: 8 · 2024: 5 · 2023: 11 · 2022: 2
FWCI
2.20
Type
journal article
Language
en
Open access
Locations
  • Journal of Medicinal Chemistry (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion, cc-by)
  • UCL Discovery (University College London) (submittedVersion)
  • Huddersfield Research Portal (University of Huddersfield) (submittedVersion, cc-by)
Funders
  • School of Pharmacy, University College London
  • Royal Society of Chemistry
  • University College London
  • Biotechnology and Biological Sciences Research Council (BB/L01923X/1)
  • Cancer Research UK (C9344/A10268)
  • Maplethorpe Trust
  • Bloomsbury Consortium
  • MRC Proximity to Discovery
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
Keywords
Keap1, Nrf2, protein-protein interaction inhibitors, ubiquitination, drug detoxification, redox homeostasis, Alzheimer's disease, Parkinson's disease, vascular inflammation, chronic obstructive pulmonary disease
MeSH terms
Kelch-Like ECH-Associated Protein 1, Protein Binding, Sulfonamides, NF-E2-Related Factor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode. https://app.cochat.ai/papers/10.1021/acs.jmedchem.2c00457
The paper
Georgakopoulos, N., Talapatra, S., Dikovskaya, D., Dayalan Naidu, S., Higgins, M., Gatliff, J., Ayhan, A., Nikoloudaki, R., Schaap, M., Valko, K., Javid, F., Dinkova-Kostova, A. T., Kozielski, F., & Wells, G. (2022). Phenyl Bis-Sulfonamide Keap1-Nrf2 Protein–Protein Interaction Inhibitors with an Alternative Binding Mode. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c00457

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.